DE-QPS/SCANTOX
30.11.2023 14:16:35 CET | Business Wire | Press release
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/
QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)
Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organization as a desirable acquisition target. QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees. With on-site availability of validated transgenic and non-transgenic in-vitro and in-vivo models, QPS Neuropharmacology addresses multiple targets within the growing CNS area and represents a unique partner for biotech and pharma companies in their drug development process.
After the sale is complete, QPS will retain the European clinical division including the service capbilities in Austria, The Czech Republic, and Croatia where QPS has a long history of conducting late-phase clinical trials in neurodegenerative diseases, oncology and various rare diseases. This late-phase clinical capability will remain fully integrated with the QPS global clinical operational services organization, providing comprehensive global CRO services to pharmaceutical and biotech clients worldwide.
“The sale of QPS Neuropharmacology is a natural transition in the development of QPS as a full-service, global CRO focused on preclinical, bioanalysis and clinical research operational services. We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” says Ben Chien, President and CEO of QPS Holdings, LLC.
Manuela Prokesch, Director of QPS Neuropharmacology, continues: “This is a unique opportunity for us to bring our deep Neuropharmacology expertise to join a preclinical market leader, known for their high quality and customer-centric approach. We are looking forward to continuing to deliver our signature high-quality solutions to our clients while leveraging the synergies we can generate across the Scantox organization”.
QPS Neuropharmacology will continue to serve its valued clients as part of the Scantox organization. The combined company will have more than 300 employees across six sites offering lead optimization, neuropharmacology research services, regulatory toxicology and CMC/analytical services.
Advisors
Perella Weinberg Partners is serving as financial advisor to QPS Holdings, KPMG is serving as its tax advisor and Ropes & Gray together with Wolf Theiss are serving as its legal counsel. Lincoln International is serving as corporate finance advisor to Scantox, EY is serving as its financial and tax advisor, L.E.K. Consulting as its commercial advisor and Accura together with DORDA are serving as its legal counsel.
About QPS Holdings, LLC:
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
About Scantox:
Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with three subsidiaries in Sweden and one in Denmark. Based on decades of experience, the company is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs. The Company’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is owned by Impilo, a leading Nordic healthcare investment company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130940694/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elliptic Sets the Engineering Bar for On-Chain Risk With “Built for Compliance” Paper as New Rules Take Hold and Banks Launch a Joint Stablecoin1.10.2026 15:40:00 CEST | Press release
Built for compliance arrives as crypto compliance rules tighten worldwide and a bank-led stablecoin enters the market Elliptic, the global leader in on-chain risk management, today published Built for compliance, a paper setting out the nine engineering decisions that determine whether an on-chain risk system can support fast, accurate and defensible compliance decisions at agentic scale. Machines are already moving money on their own, at machine speed. Compliance teams now have to make hundreds of thousands of decisions a day, at that same speed. However, many on-chain risk systems were never engineered to support that pace. A compliance system that computes exposure on a schedule delivers stale results. One that defines blockchain coverage loosely enough lets a screening miss exposure entirely. A system that skips testing disaster recovery, a spike or an outage, takes down the customer’s compliance system too. That gap between machine speed and system design is exactly what regulator
Impartner Releases AI Ecosystem Playbook to Help Organizations Move from AI Experimentation to Execution1.10.2026 15:00:00 CEST | Press release
The AI Ecosystem Playbook provides a practical framework for assessing AI readiness, identifying high-value opportunities, addressing foundational gaps, and building a roadmap for AI adoption. Impartner, the world’s leading partner revenue orchestration platform, today announced the release of its AI Ecosystem Playbook, a new resource designed to help leaders and teams assess their current AI capabilities, identify areas where AI can support business goals, and develop a practical path to implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001661549/en/ Impartner’s AI Ecosystem Playbook helps organizations assess AI readiness and identify opportunities to apply AI across PRM 3.0, partner revenue orchestration, and the partner lifecycle. As AI moves from experimentation into everyday operations, companies need more than a collection of potential applications. They need a framework for understanding where they ar
Whiteford Adds Six Partners in New York City, Expanding its Litigation, International and Corporate Practices1.10.2026 15:00:00 CEST | Press release
Lateral group joins growing Midtown Manhattan office as firm pursues targeted expansion strategy Whiteford, Taylor & Preston, a full-service law firm with offices across the East Coast, today announced that six partners from Chambers-rated Lazare Potter Glazer & Moyle LLP have joined Whiteford’s New York office: David E. Potter, James F. Moyle, Johannes K. Gäbel, Jaipat Singh Jain, Anna Pia D. Felix and Jacob Englander. This team expands Whiteford's New York office to more than two dozen attorneys and deepens the firm's commercial and securities litigation, employment, cross-border and corporate capabilities in the New York market. The six partners bring decades of combined experience representing mid-market companies, investment advisers, hedge funds, foreign corporations, entrepreneurs and executives in litigation, regulatory investigations, and complex business transactions. "We are expanding with our clients, our markets and our reputation," said Martin Fletcher, Whiteford's Managi
Skechers Enters Super Shoe Era With Innovative Skechers AERO Elite1.10.2026 14:20:00 CEST | Press release
Groundbreaking Design Gives Elite Runners the Performance to Break Barriers and Records in Any Race Skechers is redefining what it means to run fast with the Skechers AERO Elite. The latest addition to the innovative Skechers AERO Series makes its global racing debut today—marking a landmark moment as the performance brand’s first super shoe. Engineered to perform from 5Ks to marathons, the design minimizes weight and maximizes responsiveness, all while delivering Skechers’ signature comfort. The AERO Elite is built to win with the performance runners at any level need to go further, faster, and achieve that next personal record. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001865320/en/ Introducing the Skechers AERO Elite, the brand’s first super shoe designed for racing. “The Skechers AERO Elite is the culmination of years of elite-level running innovation—our most technically advanced running shoe to date and a direc
Visa Data Shows Stablecoins Gaining Traction in Business Payments1.10.2026 14:00:00 CEST | Press release
New Visa data shows nearly 17%1 of stablecoin-linked card volume is occurring across business and commercial card programs, underscoring growing adoption of stablecoins for settlement, treasury management and cross-border commerce. Today, Visa (NYSE: V) shared new data showing the growing adoption of stablecoins across business payments and commercial card programs, underscoring how stablecoins are increasingly being used as financial infrastructure. The findings come as businesses, financial institutions and payment providers increasingly explore stablecoins for settlement, treasury management, payouts and cross-border commerce. New Visa data shows: Approximately 17% of stablecoin-linked card volume in FY26 year-to-date occurred across business and commercial card programs. Visa today supports more than 160 stablecoin-linked card programs spanning consumer, business and commercial card activity. Payments volume across these programs has grown nearly 200% year over year. Businesses are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom